Halimed Pharmaceuticals Inc. is a biotechnology company developing a pipeline of drugs for affective disorders. The company's technology is centered on a proprietary peptide modification chemistry platform and intellectual properties of a portfolio of non-natural amino acid analogs of arginine (Arg) and lysine (Lys) that, when incorporated into biologically active peptides, improves their overall pharmacological profile
